With so much at stake, there is no room for compromise. Edwards SAPIEN 3 TAVI helps you:

Deliver outcomes you demand

1%

death or disabling stroke at 1 year1

Perfect the pathway through efficient procedures

96%

of patients discharged to the comfort of their home1

Control for the future to continue to meet the emerging needs of new patient populations

100%

successful post-TAVI coronary access2

For more info

Download Brochure

The valve designed to meet your Higher Standard.

Scroll / swipe side to side to review timeline

*On the primary endpoint of death, stroke, and rehospitalization at 1 year.

Clinical Study

25,000+

patients studied in Edwards clinical trials

Real world experience

450,000+

patients treated worldwide with Edwards TAVI valves

Data on file at Edwards Lifesciences.

Stay informed

References:  

1. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019.
2. Tarantini G, Fovino LN, Le Prince P, et al. Coronary access and percutaneous coronary intervention up to 3 years after transcatheter aortic valve implantation with a balloon-expandable valve. Circ Cardiovasc Interv. 2020;13(7).
3. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med. 2010.
4. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N Engl J Med. 2016.
5. Nazif T, Daniels D, McCabe J, Chehab B, et al. Real-world experience with the SAPIEN 3 Ultra TAVI: A propensity matched analysis from the United States. Presented virtually at TVT Connect 2020.